Literature DB >> 3928265

The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics.

A M Emmerson, P A Lamport, D S Reeves, M J Bywater, H A Holt, R Wise, J Andrews, M J Hall.   

Abstract

The results of a large three centre co-ordinated study into the in vitro susceptibility of bacterial clinical pathogens showed no significant evidence of regional variation within the U.K. towards the 10 antibiotics examined. The newer cephalosporins were highly potent and superior to other antibiotics against the Enterobacteriaceae, with ceftriaxone and cefotaxime the most potent. Against Pseudomonas aeruginosa, gentamicin was the most active, followed by ceftazidime, piperacillin and ceftriaxone; cefotetan was the least active. Staphylococcus aureus and Staphylococcus albus were most susceptible to cefuroxime and gentamicin, though most were also susceptible to ceftriaxone, cefotaxime and cefoxitin. Streptococcus (Groups A and B), Streptococcus pneumoniae and Neisseria spp. were susceptible to most agents other than gentamicin, but ceftriaxone and cefotaxime were overall the most potent. Ceftriaxone was the most active agent against Haemophilus influenzae. The newer agents were variable and relatively poor against anaerobes and only amoxycillin and piperacillin were significantly active against Streptococcus faecalis. The overall resistance level to the third generation cephalosporins was low.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928265     DOI: 10.1185/03007998509109622

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  7 in total

1.  An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.

Authors:  E T Smyth; J G Barr; C A O'Neill; G M Hogg
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies.

Authors:  R Nau; H W Prange; M Kinzig; A Frank; A Dressel; P Scholz; H Kolenda; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Effects of macro- and microcirculatory functions on ceftriaxone concentrations in tissues of patients with stage IV peripheral arterial occlusive disease.

Authors:  M Hirschl; M Kundi; A M Hirschl; A Georgopoulos
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  Concentrations in plasma and tissue penetration of ceftriaxone and ornidazole during liver transplantation.

Authors:  A Steib; B Jacoberger; M Von Bandel; F Beck; J P Beller; K Boudjema; J C Koffel; J C Otteni
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.

Authors:  R Nau; H W Prange; P Muth; G Mahr; S Menck; H Kolenda; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.